 |
市場調查報告書
商品編碼
2107769
纖維母細胞生長因子受體 2 (FGFR2) 抑制劑市場：按藥物、適應症、最終用戶和地區分類Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug, By Indication, By End User, By Geography |
||||||
預計2026年，纖維母細胞生長因子受體2（FGFR2）抑制劑市場規模將達1.963億美元，到2033年將達到5.54億美元。預計從2026年到2033年，該市場將以16.0%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 1.963億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 16.00% | 2033年市場規模預測： | 5.54億美元 |
纖維母細胞生長因子受體2 (FGFR2) 抑制劑是一種標靶療法，可阻斷異常的FGFR2訊號傳導。這種異常訊號傳導是由基因融合、突變和擴增等多種因素引起的，常見於胃癌、子宮乳癌和肝內膽管癌等疾病。這種靶向調控癌細胞增殖、存活和血管生成的訊號通路的標靶治療策略，已發展成為精準腫瘤學領域極為重要的治療方法。
由於以生物標記為導向的癌症治療趨勢日益成長、基因組分析技術的應用不斷擴展，以及對基於FGFR2的腫瘤生物學過程的理解不斷加深，全球纖維母細胞生長因子受體2 (FGFR2) 抑製劑市場預計將迎來成長勢頭。此外，特定FGFR抑制劑核准和核准適應症數量的增加，以及診斷方法與伴隨檢測相結合的持續發展，有助於識別適合使用FGFR2標靶藥物的患者群體，從而推動市場擴張。 FGFR2抑制劑治療在已開發市場和開發中國家市場均持續受到關注。
市場動態
全球纖維母細胞生長因子受體2 (FGFR2) 抑制劑市場正受到FGFR2突變相關癌症（尤其是膽管癌）發生率的上升所推動。此外，基因組分析和伴隨診斷在精準確定FGFR2標靶藥物合格方面的應用日益廣泛，以及監管部門的批准，也促進了市場成長。同時，下一代選擇性FGFR2抑制劑的研發管線預計將在推動市場發展方面發揮重要作用。製藥公司、生技公司和研究機構之間的策略合作將進一步加快FGFR2抑制劑研發管線的開發步伐。
然而，該市場面臨諸多限制，包括標靶治療費用過高、許多地區缺乏足夠的保險報銷制度以及FGFR2突變患者群體規模有限。
儘管如此，專注於下一代 FGFR2 抑制劑的研發管線取得了重大進展，聯合治療的應用以及分子診斷在發展中市場日益普及，將為纖維母細胞生長因子受體 2 (FGFR2) 抑制劑市場創造新的成長機會。
本次調查的主要特點
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數，介紹了全球纖維母細胞生長因子受體 2 (FGFR2) 抑制劑市場的主要公司概況：公司概況、產品系列、主要亮點、財務績效和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球纖維母細胞生長因子受體 2 (FGFR2) 抑制劑市場」報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以利用全球纖維母細胞生長因子受體 2 (FGFR2) 抑制劑市場分析中使用的各種策略矩陣來促進決策。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特的分析
- 市場機遇
- 監管趨勢
- 產業趨勢
第4章 全球纖維母細胞生長因子受體2 (FGFR2) 抑制劑市場：依藥物分類，2021-2033年
- 培米加替尼
- 福奇巴希尼
- 塔蘇格拉替尼
- 替諾替尼
- 利拉夫格拉替尼
第5章 全球纖維母細胞生長因子受體2 (FGFR2) 抑制劑市場：依適應症分類，2021-2033年
- 膽管癌
- 胃癌
- 子宮內膜癌
- 其他
第6章 全球纖維母細胞生長因子受體2 (FGFR2) 抑制劑市場：依最終用戶分類，2021-2033年
- 醫院
- 專科診所
- 癌症中心
- 其他
第7章 全球纖維母細胞生長因子受體2 (FGFR2) 抑制劑市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第8章 競爭情勢
- 公司簡介
- Incyte Corporation
- Taiho Pharmaceutical Co., Ltd.
- Relay Therapeutics, Inc.
- Janssen Pharmaceuticals
- BridgeBio Pharma, Inc.
- Tyra Biosciences, Inc.
- Abbisko Therapeutics Co., Ltd.
- AstraZeneca PLC
- Kinnate Biopharma Inc.
- Novartis AG
第9章 分析師建議
- 機會分析
- 分析師意見
- Coherent Opportunity Map
第10章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
Fibroblast Growth Factor Receptor 2 Inhibitor Market is estimated to be valued at USD 196.3 Mn in 2026 and is expected to reach USD 554.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 16.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 196.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 16.00% | 2033 Value Projection: | USD 554.0 Mn |
Fibroblast growth factor receptor 2 (FGFR2) inhibitors are targeted therapeutic drugs that are a part of a group of medications to halt unusual FGFR2 signaling through various factors including genetic fusions, mutations, and amplification in diseases such as gastric and uterine cancer, breast cancer, intrahepatic cholangiocarcinoma. This treatment strategy targeting signaling pathways that regulate proliferation, survival of cancer cells and angiogenesis has evolved as a crucial treatment regimen in the precision oncology sector.
The global fibroblast growth factor receptor 2 inhibitor market will gain momentum due to rising trends for cancer treatment focused on biomarkers, growing utilization of genome profiling technologies and heightened knowledge of FGFR2-based tumor biological processes. Moreover, the number of approvals and designations granted to specific FGFR inhibitors coupled with ongoing development of diagnostics paired along with companion tests has a capacity to identify eligible population for FGFR2-targeted drugs and aids market augmentation. FGFR2 inhibitor treatment also continues to gain traction across developed and developing markets.
Market Dynamics
The global fibroblast growth factor receptor 2 inhibitor market is driven by increasing incidences of FGFR2-altered cancers, especially cholangiocarcinoma. Moreover, the increasing prescription rates of genomic profiling and companion diagnostics to accurately determine the eligibility of patients for the utilization of FGFR2-targeted agents and regulatory approvals. Additionally, pipeline progress associated with the next-generation selective FGFR2 inhibitors are expected to play a critical role in propelling the market. Also, strategic partnerships among pharmaceutical organizations, biotechnology companies and research institutions will further strengthen the pace of the FGFR2 inhibitors pipeline.
However, a number of constraints are present in the market, such as prohibitively expensive nature of targeted therapies, lack of adequate reimbursement facilities across numerous regions, and limited patient pool affected by FGFR2 alterations.
Nevertheless, extensive pipeline progress focused on next-generation FGFR2 inhibitors, application of combinatorial therapy and increase in reach of molecular diagnostics in developing markets will offer new opportunities for growth in fibroblast growth factor receptor 2 inhibitor market.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global fibroblast growth factor receptor 2 inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Incyte Corporation, Taiho Pharmaceutical Co., Ltd., Relay Therapeutics, Inc., Janssen Pharmaceuticals, BridgeBio Pharma, Inc., Tyra Biosciences, Inc., Abbisko Therapeutics Co., Ltd., AstraZeneca PLC, Kinnate Biopharma Inc., and Novartis AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global fibroblast growth factor receptor 2 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibroblast growth factor receptor 2 inhibitor market
Market Segmentation
- Drug Insights (Revenue, USD Mn, 2021 - 2033)
- Pemigatinib
- Futibatinib
- Tasurgratinib
- Tinengotinib
- Lirafugratinib
- Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Cholangiocarcinoma
- Gastric Cancer
- Endometrial Cancer
- Others
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Cancer Centers
- Others
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Incyte Corporation
- Taiho Pharmaceutical Co., Ltd.
- Relay Therapeutics, Inc.
- Janssen Pharmaceuticals
- BridgeBio Pharma, Inc.
- Tyra Biosciences, Inc.
- Abbisko Therapeutics Co., Ltd.
- AstraZeneca PLC
- Kinnate Biopharma Inc.
- Novartis AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug
- Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Indication
- Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By End User
- Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pemigatinib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Futibatinib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Tasurgratinib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Tinengotinib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Lirafugratinib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Indication, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cholangiocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Gastric Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Endometrial Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By End User, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Cancer Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Company Profile
- Incyte Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Taiho Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Relay Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BridgeBio Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Tyra Biosciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbisko Therapeutics Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kinnate Biopharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Incyte Corporation
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
Eylea市場：2026-2032年全球市場預測（依適應症、給藥頻率、最終用戶和通路分類）
原體生成素藥物市場規模、佔有率和成長分析：按藥物類型、應用領域、給藥途徑、最終用戶和地區分類－2026-2033年產業預測